Upgrade to SI Premium - Free Trial

Teladoc (TDOC) Tops Q4 EPS by 1c, Revenues Beat; Q1 & FY19 EPS Guidance Above Consensus, Q1 & FY19 Revenue Guidance Below Consensus

February 27, 2019 4:05 PM

Teladoc (NYSE: TDOC) reported Q4 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $122.74 million versus the consensus estimate of $120 million.

“We had an exceptional 2018 with solid performance across all of our key financial and operational metrics, enabling us to enter 2019 with significant momentum. As virtual care becomes mainstream, we are uniquely positioned across all of our channels as the only global comprehensive virtual healthcare solution,” said Jason Gorevic, chief executive officer, Teladoc Health. “We continue to extend our leadership position by delivering the highest quality care, successfully engaging consumers, broadening our scope of services, and expanding our global geographic reach.”

GUIDANCE:

Teladoc sees Q1 2019 EPS of ($0.46)-($0.44), versus the consensus of ($0.31). Teladoc sees Q1 2019 revenue of $126-129 million, versus the consensus of $131 million.

Teladoc sees FY2019 EPS of ($1.66)-($1.52), versus the consensus of ($1.08). Teladoc sees FY2019 revenue of $535-545 million, versus the consensus of $547.83 million.

Financial OutlookTeladoc Health provides guidance based on current market conditions and expectations.

For the first-quarter 2019, we expect:

For the full-year 2019, we expect:

For earnings history and earnings-related data on Teladoc (TDOC) click here.

Categories

Corporate News Earnings Guidance Hot Guidance Management Comments

Next Articles